Epigenetic changes in diabetes

Neuroscience Letters

Volumn 625, Issue , 2016, Pages 64-69

  Al Haddad, Rami ^a   Karnib, Nabil ^a   Assaad, Rawad Abi ^a   Bilen, Yara ^a   Emmanuel, Nancy ^a   Ghanem, Anthony ^a   Younes, Joe ^a   Zibara, Victor ^a   Stephan, Joseph S ^a   Sleiman, Sama F ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

Diabetes; DNA methylation; Epigenetics; HDACs

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DNA; DNA METHYLTRANSFERASE 1; GLUCAGON; GLUCOSE; GLUCOSE TRANSPORTER 4; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HISTONE METHYLTRANSFERASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1; MICRORNA; MICRORNA 10B; MICRORNA 222; MICRORNA 375; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR PDX 1; UNTRANSLATED RNA;

AUTOPHOSPHORYLATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL TRANSDIFFERENTIATION; CPG ISLAND; DEACETYLATION; DIABETES MELLITUS; DNA METHYLATION; ENHANCER REGION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLUCAGON RELEASE; GLUCOSE TRANSPORT; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; HUMAN; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HISTONE CODE;

ANIMALS; DIABETES MELLITUS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONE CODE; HUMANS; RNA, UNTRANSLATED;

EID: 84964870432     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.04.046     Document Type: Review

References (88)

1. American Diabetes A. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013, 36(4):1033-1046.
2. Hogan P., et al. Economic costs of diabetes in the US in 2002. Diabetes Care 2003, 26(3):917-932.
3. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87(1):4-14.
4. Ashcroft F.M., Rorsman P. Diabetes mellitus and the beta cell: the last ten years. Cell 2012, 148(6):1160-1171.
5. Hirschhorn J.N., Daly M.J. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 2005, 6(2):95-108.
6. Todd J.A. Etiology of type 1 diabetes. Immunity 2010, 32(4):457-467.
7. Bonnefond A., Froguel P., Vaxillaire M. The emerging genetics of type 2 diabetes. Trends Mol. Med. 2010, 16(9):407-416.
8. McCarthy M.I. Genomics: type 2 diabetes, and obesity. N. Engl. J. Med. 2010, 363(24):2339-2350.
9. Kirkpatrick C.L., et al. Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS One 2010, 5(6):e11053.
10. Lyssenko V., et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 2007, 117(8):2155-2163.
11. Guo S., et al. Inactivation of specific beta cell transcription factors in type 2 diabetes. J. Clin. Invest. 2013, 123(8):3305-3316.
12. Halban P.A., et al. beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014, 37(6):1751-1758.
13. Talchai C., et al. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 2012, 150(6):1223-1234.
14. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 53(Suppl. 3):S16-S21.
15. Domingueti C.P., et al. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J. Diabetes Complicat. 2015.
16. Vinik A., Casellini C., Nevoret M.L., et al. Diabetic neuropathies. Endotext 2000, South Dartmouth (MA). L.J. De Groot (Ed.).
17. Sayyid R.K., Fleshner N.E. Diabetes mellitus type 2: a driving force for urological complications. Trends Endocrinol. Metab. 2016.
18. Cai X., McGinnis J.F. Diabetic retinopathy: animal models, therapies, and perspectives. J. Diabetes. Res. 2016, 2016. (3789217).
19. Scheen A.J. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion?. Diabetes Metab. 2005, 31:5S27. (Sec2).
20. Mercado M.M., et al. Genetics of insulin resistance. Curr. Diabetes Rep. 2002, 2(1):83-95.
21. Ling C., Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 2009, 58(12):2718-2725.
22. Bird A. Perceptions of epigenetics. Nature 2007, 447(7143):396-398.
23. Schubeler D. Function and information content of DNA methylation. Nature 2015, 517(7534):321-326.
24. Dhawan S., et al. Pancreatic beta cell identity is maintained by DNA methylation-mediated repression of Arx. Dev. Cell 2011, 20(4):419-429.
25. Yang B.T., et al. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. Mol. Endocrinol. 2012, 26(7):1203-1212.
26. Ishikawa K., et al. Long-term pancreatic beta cell exposure to high levels of glucose but not palmitate induces DNA methylation within the insulin gene promoter and represses transcriptional activity. PLoS One 2015, 10(2):e0115350.
27. Akinci E., et al. Reprogramming of pancreatic exocrine cells towards a beta (beta) cell character using Pdx1: Ngn3 and MafA. Biochem. J 2012, 442(3):539-550.
28. Katz L.S., Geras-Raaka E., Gershengorn M.C. Reprogramming adult human dermal fibroblasts to islet-like cells by epigenetic modification coupled to transcription factor modulation. Stem Cells Dev. 2013, 22(18):2551-2560.
29. Wang Q., et al. The reprogrammed pancreatic progenitor-like intermediate state of hepatic cells is more susceptible to pancreatic beta cell differentiation. J. Cell Sci. 2013, 126(Pt 16):3638-3648.
30. Dayeh T., et al. Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion. PLoS Genet. 2014, 10(3):e1004160.
31. Olsson A.H. et al. Genome-wide associations between genetic and epigenetic variation influence mRNA expression and insulin secretion in human pancreatic islets. PLoS Genet. 2014, 10(11):e1004735.
32. Ling C., et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008, 51(4):615-622.
33. Alibegovic A.C., et al. Insulin resistance induced by physical inactivity is associated with multiple transcriptional changes in skeletal muscle in young men. Am. J. Physiol. Endocrinol. Metab. 2010, 299(5):E752-63.
34. Bell C.G., et al. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med. Genomics 2010, 3:33.
35. Tregouet D.A., et al. G/T substitution in intron 1 of the UNC13B gene is associated with increased risk of nephropathy in patients with type 1 diabetes. Diabetes 2008, 57(10):2843-2850.
36. Maganti A.V., et al. Transcriptional activity of the islet beta cell factor Pdx1 is augmented by lysine methylation catalyzed by the methyltransferase Set7/9. J. Biol. Chem. 2015, 290(15):9812-9822.
37. Christensen D.P., et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol. Med. 2011, 17(5-6):378-390.
38. Willcox A., et al. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009, 155(2):173-181.
39. Brasacchio D., et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009, 58(5):1229-1236.
40. Pradhan S., et al. SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics 2009, 4(6):383-387.
41. Miao F., et al. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 2008, 57(12):3189-3198.
42. Villeneuve L.M., Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am. J. Physiol. Renal Physiol. 2010, 299(1):F14-25.
43. Zhong Q., Kowluru R.A. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 2011, 60(4):1304-1313.
44. Zhong Q., Kowluru R.A. Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation. Invest. Ophthalmol. Vis. Sci. 2013, 54(1):244-250.
45. Danforth E. Failure of adipocyte differentiation causes type II diabetes mellitus?. Nat. Genet. 2000, 26(1):13.
46. Fujimoto S., Goda T., Mochizuki K. In vivo evidence of enhanced di-methylation of histone H3 K4 on upregulated genes in adipose tissue of diabetic db/db mice. Biochem. Biophys. Res. Commun. 2011, 404(1):223-227.
47. Janani C., Ranjitha Kumari B.D. PPAR gamma gene?a review. Diabetes Metab. Syndr. 2015, 9(1):46-50.
48. Tateishi K., et al. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature 2009, 458(7239):757-761.
49. Nerup J., Pociot F., I.S. European Consortium A genomewide scan for type 1-diabetes susceptibility in Scandinavian families: identification of new loci with evidence of interactions. Am. J. Hum. Genet. 2001, 69(6):1301-1313.
50. Xiang K., et al. Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes 2004, 53(1):228-234.
51. Poulsen P., et al. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance-a population-based twin study. Diabetologia 1999, 42(2):139-145.
52. Redondo M.J., Fain P.R., Eisenbarth G.S. Genetics of type 1A diabetes. Recent Prog. Horm. Res. 2001, 56:69-89.
53. Park J.H., et al. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J. Clin. Invest. 2008, 118(6):2316-2324.
54. Pinney S.E., Simmons R.A. Epigenetic mechanisms in the development of type 2 diabetes. Trends Endocrinol. Metab. 2010, 21(4):223-229.
55. Raychaudhuri N., et al. Histone code modifications repress glucose transporter 4 expression in the intrauterine growth-restricted offspring. J. Biol. Chem. 2008, 283(20):13611-13626.
56. Mosley A.L., Ozcan S. Glucose regulates insulin gene transcription by hyperacetylation of histone h4. J. Biol. Chem. 2003, 278(22):19660-19666.
57. Mosley A.L., Corbett J.A., Ozcan S. Glucose regulation of insulin gene expression requires the recruitment of p300 by the beta-cell-specific transcription factor Pdx-1. Mol. Endocrinol. 2004, 18(9):2279-2290.
58. Mosley A.L., Ozcan S. The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose. J. Biol. Chem. 2004, 279(52):54241-54242.
59. Deering T.G., et al. Methyltransferase Set7/9 maintains transcription and euchromatin structure at islet-enriched genes. Diabetes 2009, 58(1):185-193.
60. Takigawa-Imamura H., et al. Stimulation of glucose uptake in muscle cells by prolonged treatment with scriptide: a histone deacetylase inhibitor. Biosci. Biotechnol. Biochem. 2003, 67(7):1499-1506.
61. McGee S.L., et al. AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes 2008, 57(4):860-867.
62. McKinsey T.A., Zhang C.L., Olson E.N. Control of muscle development by dueling HATs and HDACs. Curr. Opin. Genet. Dev. 2001, 11(5):497-504.
63. Sparling D.P., et al. GLUT4 enhancer factor (GEF) interacts with MEF2A and HDAC5 to regulate the GLUT4 promoter in adipocytes. J. Biol. Chem. 2008, 283(12):7429-7437.
64. McKinsey T.A., Zhang C.L., Olson E.N. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(26):14400-14405.
65. McGee S.L., Hargreaves M. Exercise and myocyte enhancer factor 2 regulation in human skeletal muscle. Diabetes 2004, 53(5):1208-1214.
66. Michael L.F., et al. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(7):3820-3825.
67. Crunkhorn S., et al. Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. J. Biol. Chem. 2007, 282(21):15439-15450.
68. Kaiser C., James S.R. Acetylation of insulin receptor substrate-1 is permissive for tyrosine phosphorylation. BMC Biol. 2004, 2:23.
69. Kadiyala C.S., et al. Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC). J. Biol. Chem. 2012, 287(31):25869-25880.
70. Miao F., et al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J. Biol. Chem. 2004, 279(17):18091-18097.
71. Winer D.A., et al. The intestinal immune system in obesity and insulin resistance. Cell Metab. 2016, 23(3):413-426.
72. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259(5091):87-91.
73. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72:219-246.
74. Biddinger S.B., Kahn C.R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 2006, 68:123-158.
75. Yun J.M., Jialal I., Devaraj S. Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J. Nutr. Biochem. 2011, 22(5):450-458.
76. Perrone L., et al. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J. Cell. Physiol. 2009, 221(1):262-272.
77. Crosson C.E., et al. Inhibition of histone deacetylase protects the retina from ischemic injury. Invest. Ophthalmol. Vis. Sci. 2010, 51(7):3639-3645.
78. Patel T., et al. Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice. Immunol. Cell Biol. 2011, 89(5):640-649.
79. Galmozzi A., et al. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes 2013, 62(3):732-742.
80. Filios S.R., Shalev A. Beta-cell MicroRNAs: small but powerful. Diabetes 2015, 64(11):3631-3644.
81. Melton C., Judson R.L., Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature 2010, 463(7281):621-626.
82. Yamakuchi M., Ferlito M., Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(36):13421-13426.
83. Huntzinger E., Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet. 2011, 12(2):99-110.
84. Guay C., et al. Emerging roles of non-coding RNAs in pancreatic beta-cell function and dysfunction. Diabetes Obes. Metab. 2012, 14(Suppl. 3):12-21.
85. Herrera B.M., et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010, 53(6):1099-1109.
86. Hezova R., et al. microRNA-342: microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol. 2010, 260(2):70-74.
87. Poy M.N., et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432(7014):226-230.
88. Xu G., et al. Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat. Med. 2013, 19(9):1141-1146.